Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $14.00 price target on the stock.
Cognition Therapeutics, Inc. (CGTX)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
CGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGTX alerts
High impacting Cognition Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGTX
News
- Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 [Yahoo! Finance]Yahoo! Finance
- Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025GlobeNewswire
- Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its price target lowered by analysts at Chardan Capital from $11.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
CGTX
Earnings
- 3/20/25 - Miss
CGTX
Sec Filings
- 3/20/25 - Form 424B5
- 3/20/25 - Form S-8
- 3/20/25 - Form 10-K
- CGTX's page on the SEC website